2023
DOI: 10.1016/j.chest.2023.03.040
|View full text |Cite
|
Sign up to set email alerts
|

Valaciclovir for Epstein-Barr Virus Suppression in Moderate-to-Severe COPD

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 37 publications
0
1
0
Order By: Relevance
“…In our patient there were initial concerns for hemophagocytic lymphohistiocytosis given the recognised role of EBV in precipitating similar reactions in other inborn errors of immunity. Valaciclovir is an inhibitor of EBV replication and has been suggested to be an adjunct therapy in the treatment of hemophagocytic lymphohistiocytosis and has been shown to inhibit viral shedding [ 16 18 ]. In our patient, a continuous reduction in quantitated levels of EBV without the addition of other immunomodulators was noted, with elimination of viraemia over 8 weeks.…”
Section: Discussionmentioning
confidence: 99%
“…In our patient there were initial concerns for hemophagocytic lymphohistiocytosis given the recognised role of EBV in precipitating similar reactions in other inborn errors of immunity. Valaciclovir is an inhibitor of EBV replication and has been suggested to be an adjunct therapy in the treatment of hemophagocytic lymphohistiocytosis and has been shown to inhibit viral shedding [ 16 18 ]. In our patient, a continuous reduction in quantitated levels of EBV without the addition of other immunomodulators was noted, with elimination of viraemia over 8 weeks.…”
Section: Discussionmentioning
confidence: 99%